PreveCeutical Medical Inc (18H) - Total Liabilities

Latest as of September 2025: €7.85 Million EUR ≈ $9.18 Million USD

Based on the latest financial reports, PreveCeutical Medical Inc (18H) has total liabilities worth €7.85 Million EUR (≈ $9.18 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore PreveCeutical Medical Inc (18H) net asset momentum to track the company's year-over-year net asset growth rate.

PreveCeutical Medical Inc - Total Liabilities Trend (2016–2024)

This chart illustrates how PreveCeutical Medical Inc's total liabilities have evolved over time, based on quarterly financial data. See PreveCeutical Medical Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

PreveCeutical Medical Inc Competitors by Total Liabilities

The table below lists competitors of PreveCeutical Medical Inc ranked by their total liabilities.

Company Country Total Liabilities
Immersion SA
PA:ALIMR
France €3.77 Million
EMPYREAN ENERGY LS-002
F:E1E
Germany €12.88 Million
REDSUN PROPERTIES GROUP
F:0RJ
Germany €52.83 Billion
Agereh Technologies Inc
V:AUTO
Canada CA$6.35 Million
iSpecimen Inc
NASDAQ:ISPC
USA $5.80 Million
Weaccess Group SA
PA:MLWEA
France €1.16 Million
BPH Global Ltd
AU:BP8
Australia AU$2.01 Million
CPD SA
WAR:CPD
Poland zł970.00K

Liability Composition Analysis (2016–2024)

This chart breaks down PreveCeutical Medical Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 18H market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.04 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.05 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 17.21 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how PreveCeutical Medical Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for PreveCeutical Medical Inc (2016–2024)

The table below shows the annual total liabilities of PreveCeutical Medical Inc from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 €6.86 Million
≈ $8.02 Million
+15.15%
2023-12-31 €5.96 Million
≈ $6.97 Million
+23.54%
2022-12-31 €4.82 Million
≈ $5.64 Million
+13.11%
2021-12-31 €4.27 Million
≈ $4.99 Million
+9.19%
2020-12-31 €3.91 Million
≈ $4.57 Million
-26.91%
2019-12-31 €5.34 Million
≈ $6.25 Million
+27.64%
2018-12-31 €4.19 Million
≈ $4.90 Million
+42.23%
2017-12-31 €2.94 Million
≈ $3.44 Million
+485.00%
2016-12-31 €503.24K
≈ $588.35K
--

About PreveCeutical Medical Inc

F:18H Germany Biotechnology
Market Cap
$3.34 Million
€2.85 Million EUR
Market Cap Rank
#29314 Global
#2544 in Germany
Share Price
€0.01
Change (1 day)
-54.55%
52-Week Range
€0.01 - €0.03
All Time High
€0.13
About

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disor… Read more